Developer of molecular-cell diagnostic technology intended to develop antibodies for cancer diagnosis. The company's technology uses recombinant diagnosis and long-established hybridoma lines for the development of antibodies, enabling the healthcare industry to treat cancer easily.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC | 25-Sep-2017 | 00.000 | Completed | Generating Revenue | ||
2. Early Stage VC | 00.000 | Completed | Startup | |||
1. Early Stage VC (Series A) | 01-Jan-2013 | $2.02M | $2.02M | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Alexey Grachev Ph.D | Co-Founder, General Director & Chief Executive Officer | ||
Juliya Kzhyshkovska | Co-Founder | ||
Olga Lopaeva | Co-Founder |
Growth Rate
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Russian Venture Company | Venture Capital | Majority | 000 0000 | 000000 0 | |
Skolkovo Foundation | Limited Partner | Minority | 000 0000 | 000000 0 |